Pembrolizumab by Leila Khoja et al.
Khoja et al. Journal for ImmunoTherapy of Cancer  (2015) 3:36 
DOI 10.1186/s40425-015-0078-9REVIEW Open AccessPembrolizumab
Leila Khoja1, Marcus O. Butler1, S. Peter Kang2, Scot Ebbinghaus2 and Anthony M. Joshua1*Abstract
The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011
for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents
against the programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis have shown
significant activity in melanoma and a variety of other tumor types. Pembrolizumab was the first anti-PD-1 antibody
to be approved by the US Food and Drug Administration for the treatment of patients with unresectable or
metastatic melanoma with disease progression following ipilimumab, and if BRAFV600 mutation positive, a BRAF
inhibitor. Pembrolizumab has also received breakthrough status for the treatment of EGFR mutation-negative, ALK
rearrangement-negative non-small cell lung cancer (NSCLC) that has progressed on or following platinum-based
chemotherapy. There remain a number of pivotal trials in progress to further evaluate the optimal use of pembrolizumab
alone and in combination for melanoma, NSCLC, and other tumor types. In this article, we review the efficacy
and toxicity profile of pembrolizumab and evaluate its future development.
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Programmed death receptor ligand 1Introduction
Discovered in 1992, programmed death receptor 1 (PD-1)
is a member of the B7-CD28 superfamily [1]. It is expressed
on activated T (CD8+ and CD4+) cells, B cells, monocytes,
natural killer T cells, and antigen-presenting cells (APC), in-
cluding dendritic cells. Generation of PD-1-deficient mice
showed that this receptor has an immune-regulatory role in
inducing peripheral tolerance [1–3] and modulating the
magnitude of the antigen-specific immune response to in-
fection [4–6] and cancer [7–9]. Inflammation-induced cyto-
kines produced as a result of infection or tumor formation
induce the expression of programmed death receptor lig-
and 1 (PD-L1) on various cell types, including APC, and
programmed death receptor ligand 2 (PD-L2) on APC.
The PD-1/PD-L1/PD-L2 interaction negatively affects
the function of T and B cells, leading to decreased cyto-
kine production and antibody formation, thereby inhi-
biting autoimmunity and anti-tumor and anti-infectious
immunity [10]. Lymphocyte activation relies on antigen
recognition by specific T-cell antigen receptors (aided
by APCs) and regulation thereafter of that activation by* Correspondence: Anthony.Joshua@uhn.ca
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creativecommons.org/publicdomain/zero/1.0/stimulatory and inhibitory signals from T-cell co-receptors.
Co-stimulatory receptors include CD28, ICOS, 41BB, and
OX40, whilst CTLA-4, VISTA, Tim-3, and PD-1 are co-
inhibitory. Dynamic interactions occur between the
APC, tumor cell, and T cell that govern whether T-cell
activation can occur, and if so, the magnitude and dur-
ation of that activity. The role of the various co-
stimulatory or co-inhibitory molecules in controlling
this interaction is yet to be fully understood, but might
well differ within and between patients’ tumor lesions.
The role of monocytes or macrophages in this inter-
action is also under investigation.
The successful development of therapeutic agents
targeting the PD-1/PD-L1 axis has been a major thera-
peutic advancement in oncology. In this article we dis-
cuss the development of pembrolizumab, the first
anti–PD-1 agent to be approved by the US Food and
Drug Administration (FDA). Pembrolizumab is also
approved for use in melanoma in Australia, Israel,
Korea, Macau, and the United Arab Emirates and was
recently recommended for approval in the European
Union.icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Phase I data
Pembrolizumab (previously known as MK-3475 and
lambrolizumab) is a potent, highly selective, fully hu-
manized immunoglobulin (Ig) G4-kappa monoclonal
antibody against PD-1. The phase I KEYNOTE-001
study (ClinicalTrials.gov identifier: NCT01295827) in-
cluded the first-in-human dose-finding cohort (part A)
that assessed pembrolizumab given intravenously at
1 mg/kg, 2 mg/kg, 3 mg/kg, and 10 mg/kg once every
2 weeks (Q2W) or every 3 weeks (Q3W) [11] and
expansion cohorts exploring the safety and antitumor
activity of several pembrolizumab doses and schedules
in patients with advanced melanoma (parts B and D)
and non-small cell lung cancer (NSCLC) (parts C and F)
(Fig. 1).
Melanoma
Based on the first-in-human experience, KEYNOTE-001
was expanded to further explore the safety and efficacy
of pembrolizumab in patients with melanoma. Initially,
patients with ipilimumab-naive and ipilimumab-treated
melanoma were given 10 mg/kg Q2W. Additional co-
horts were later recruited to explore pembrolizumab
doses and schedules of 2 mg/kg and 10 mg/kg givenAll patients
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Fig. 1 Flowchart summarizing the KEYNOTE-001 treatment cohorts in solid
Abbreviations: IPI ipilimumab; NSCLC non-small cell lung cancer; PD-L1 prog
every 3 weeksonce every 3 weeks (Q3W) and 10 mg/kg Q2W. One hun-
dred and thirty-five ipilimumab-treated and ipilimumab-
naive patients were enrolled in a nonrandomized fashion
[12], and 520 patients were enrolled in 1 of 3 randomized
cohorts: i) 2 or 10 mg/kg Q3W for ipilimumab-refractory
disease [13], ii) 2 or 10 mg/kg Q3W for ipilimumab-naive
disease [14], and iii) 10 mg/kg Q2W or Q3W for
ipilimumab-treated or ipilimumab-naive disease [15]
(Fig. 1). In all cohorts, patients were required to have an
Eastern Cooperative Oncology Group performance status
of 0 or 1 and stable brain metastases for at least 8 weeks
(brain magnetic resonance imaging [MRI] scans were not
required during screening). Tumor imaging was per-
formed at 12-week intervals.
The first data to be reported for pembrolizumab in
melanoma were from patients enrolled in a nonrando-
mized manner (analysis cutoff date, February 2013) [12].
For these patients, ipilimumab-treated disease was de-
fined as progression within 6 months after the first dose
of ipilimumab, and ≤3 prior treatments were allowed
[16]. Up to 2 previous treatments were allowed for all
ipilimumab-naive patients [17]. Prior treatment with
BRAF inhibitors was not mandatory for patients with
BRAF-mutant tumors [16]. Of the 135 nonrandomized
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tumors, melanoma, and NSCLC that have been reported to date.
rammed death receptor ligand 1; Q2W once every 2 weeks; Q3W once
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independent central review, and all 135 patients were
evaluable by immune-related response criteria (irRC)
[18] per investigator review [12]. The confirmed overall
response rate (ORR) across all doses was 38 % by
RECIST v1.1 and 37 % by irRC. No significant effect of
prior ipilimumab treatment was seen on response rates
(per RECIST v1.1, 38 % for ipilimumab-treated patients,
37 % for ipilimumab-naive patients) [12].
Nonrandomized data revealed numerical differences in
ORR between doses and schedules, although the 95 %
confidence intervals (CIs) largely overlapped; ORR was
52 % (95 % CI: 38–66) at 10 mg/kg Q2W (n = 52), 27 %
(95 % CI: 15–42) at 10 mg/kg Q3W (n = 45), and 25 %
(95 % CI: 9–49) at 2 mg/kg Q3W (n = 20) [12]. Of the
52 patients with confirmed or unconfirmed response, 42
remained on treatment after a median follow-up dur-
ation of 11 months. Best overall response was complete
response (CR) in 13 patients (11 %) and partial response
(PR) in 39 patients (33 %). Of note, 17 (33 %) of the
52 responders experienced stable disease (SD) at an early
response assessment, but went on to have durable re-
sponses with continued treatment [12]. Similar to the
delayed or atypical responses observed with ipilimumab
[18], a comparison of response per RECIST v1.1 and
irRC in the melanoma cohorts of KEYNOTE-001 re-
vealed unique response patterns with pembrolizumab;
7 patients (3.4 %) had early pseudoprogression and 8 pa-
tients (3.9 %) had delayed pseudoprogression [19]. Fur-
ther validation of irRC is ongoing, but the patterns of
response observed to date may have implications for op-
timal management for patients on anti-PD-1 agents [19].
After an additional period of follow-up (analysis cutoff
date, October 2013), the confirmed ORR by RECIST
v1.1 was 41 %, 87 % of responses were ongoing, and an
initial CR was observed after as many as 62 weeks of
treatment [17]. In a combined analysis across doses, me-
dian progression-free survival (PFS) was 7 months.
Based on a cutoff date of May 2014, median overall sur-
vival (OS) was not reached, and estimated OS at 12 and
18 months was 81 % and 71 %, respectively [17]. The
highest rate of treatment-related adverse events (AEs)
was seen at 10 mg/kg Q2W (23 %, compared with 4 %
at 10 mg/kg Q3W and 9 % at 2 mg/kg Q3W) [17]. The
higher rate of AEs at the 10 mg/kg Q2W dose may be
due to the higher amount of drug delivered over time,
but may also be secondary to a longer follow-up dur-
ation or potentially, a reflection of the Q2W schedule,
which provides patients with more opportunities to re-
port AEs. Treatment was deemed to be safe at all
doses, with 13 % of patients experiencing grade 3/4
toxicities [12].
One of the randomized cohorts of KEYNOTE-001 in-
cluded 173 ipilimumab-refractory patients who wererandomly assigned to pembrolizumab 2 mg/kg Q3W
(n = 89) or 10 mg/kg Q3W (n = 84) (Fig. 1) [13]. The
patient population was heavily pretreated, with any
number of prior therapies allowed. Seventeen percent
of patients were BRAF mutation positive (pretreatment
with targeted therapy was mandatory), and 39 % had
elevated lactate dehydrogenase (LDH) levels [13].
Ipilimumab-refractory disease was defined as confirmed
progression within 6 months after the last dose of ipili-
mumab, with ≥2 doses of ipilimumab required [16]. At
the time of reporting (analysis cutoff date, October
2013), the median follow-up duration was 8 months
[13]. ORR at both doses was 26 % per RECIST v1.1 by
central review (P = 0.96), and 42 % of patients remained
on treatment [13]. The median time to response was
12 weeks (range 7–36 weeks); 1 patient in each arm
had a CR, 25 % in each arm had PR, and SD was ob-
served in 25 % (2 mg/kg) and 24 % (10 mg/kg). Median
PFS was 22 weeks in the 2-mg/kg group and 14 weeks
in the 10-mg/kg group (hazard ratio [HR] = 0.84; 95 % CI:
0.57–1.23), with 24-week PFS rates of 45 % and 37 %,
respectively [13]. As of May 2014, median OS was not
reached; 1-year OS rates were 58 % at 2 mg/kg and 63 %
at 10 mg/kg (HR = 1.09; 95 % CI: 0.68–1.75) [13]. Eighty-
two percent of patients in each arm experienced a
treatment-related AE; the occurrence of treatment-related
grade 3/4 toxicities was 12 % overall, with only 5 % report-
ing a serious treatment-related AE. There was no signifi-
cant difference in the rate of AEs between the 2 arms.
Treatment discontinuation due to treatment-related tox-
icity of any grade occurred in 3 % of patients (6 % in the
2-mg/kg group and 1 % in the 10-mg/kg group) [13].
In the ipilimumab-naive randomized cohort, 103 pa-
tients were randomly assigned to receive pembrolizu-
mab 2 mg/kg (n = 51) or 10 mg/kg (n = 52) Q3W [14].
Of these patients, 27 %–41 % had elevated LDH, 49 %–
56 % had no prior treatment, and 31 %–39 % were BRAF
mutant (prior BRAF-inhibitor treatment was not
required in this cohort). After 12 months of follow-up
(analysis cutoff date, October 2013), ORR per RECIST
v1.1 was 33 % in the 2-mg/kg group and 40 % in the
10-mg/kg group (P = 0.48), with 4 CRs in each arm [14].
Median PFS was 27 weeks and 23 weeks, with 24-week
PFS rates of 50 % and 48 %, respectively. 1-year OS rates
were 72 % at 2 mg/kg and 64 % at 10 mg/kg. Median
time to response was 12 weeks (i.e., the time of the first
tumor assessment) for both doses. Treatment was well
tolerated, and although treatment-related AEs occurred
in approximately 86 % of patients, the incidence of
grade 3 or greater toxicities was 22 % in the 2-mg/kg
group and 2 % in the 10-mg/kg group. Two percent of
patients discontinued treatment in each arm because of
an AE, but these were not deemed to be treatment re-
lated [14].
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included 244 patients with ipilimumab-naive or ipilimumab-
treated disease (defined as above) who were randomly
assigned to pembrolizumab 10 mg/kg Q2W (n = 123)
or Q3W (n = 121) to further explore response and out-
come at these schedules [15]. The primary outcome
was ORR by RECIST v1.1 determined by central review.
As of the April 2014 analysis cutoff date, a total of 224
patients were evaluable for response (n =107 at Q3W
and n =117 at Q2W). ORR was 31 % in the Q3W arm
and 35 % in the Q2W arm, indicating no difference in
ORR between schedules (P = 0.5052). With Q3W dos-
ing, 3 CRs and 28 PRs were seen, whilst on Q2W dos-
ing, 6 CRs and 29 PRs were observed [15]. ORR per
RECIST v1.1 was 37 % in the ipilimumab-naive patients
(n = 113) and 30 % in the ipilimumab-treated patients
(n = 111). PFS was similar on both schedules (HR =
1.19; 95 % CI: 0.86–1.64). Treatment-related AEs were
experienced in 82 % of Q3W and 81 % of Q2W pa-
tients, while treatment-related grade 3/4 toxicities were
observed in 12 % and 15 %, respectively. Treatment-
related AEs leading to discontinuation occurred in 1 %
of Q2W patients and 3 % of Q2W patients [15].
Taken together, data from KEYNOTE-001 show sig-
nificant activity for pembrolizumab in patients with ad-
vanced melanoma, regardless of prior ipilimumab
treatment. Patients with ipilimumab-naive disease ap-
pear to have higher response rates. Notably, data from
randomized studies do not show a statistically significant
difference in activity between doses and schedules. The
majority of responses in all cohorts were observed at the
time of the first imaging assessment at week 12, and al-
though delayed response after initial SD or progressive
disease was possible, it was rare.
Based on the data obtained from the randomized co-
hort of 173 ipilimumab-refractory patients and support-
ive data from other KEYNOTE-001 melanoma cohorts,
pembrolizumab 2 mg/kg Q3W is now FDA approved for
the treatment of patients with unresectable or metastatic
melanoma with disease progression following ipilimu-
mab, and if BRAFV600mutation positive, a BRAF inhibitor.
The KEYNOTE-002 trial (ClinicalTrials.gov identifier:
NCT01704287), a randomized, controlled study in which
2 doses of pembrolizumab (2 mg/kg [n = 180] or 10 mg/kg
Q3W [n = 181]) were compared with investigator-choice
chemotherapy (n = 179), confirmed the efficacy and safety
of pembrolizumab in this population [20]. Eighty-three
percent of enrolled patients had M1c disease and 73 % re-
ceived ≥2 lines of prior therapy including ipilimumab. The
2 co-primary endpoints are PFS and OS, with ORR as a
secondary endpoint; cross over to pembrolizumab is
allowed upon progression on chemotherapy. A prespecified
interim analysis (conducted after ≥270 PFS events at a
0.25 % significance level) after a median follow-up time of10 months showed 6-month PFS (by RECIST v1.1) of 34 %
(95 % CI: 27 %–41 %) for 2 mg/kg, 38 % (95 % CI: 31 %–
45 %) for 10 mg/kg, and 16 % (95 % CI: 10 %–22 %) for
the chemotherapy group (HR = 0.57 for 2 mg/kg, 0.5 for
10 mg/kg; P = 0.0001 for either arm compared with
chemotherapy). No significant differences in PFS were
found between the 2 doses of pembrolizumab (HR = 0.91
[range, 0.71–1.16]; P= 0.44). Data on OS are awaited.
KEYNOTE-030 (ClinicalTrials.gov identifier: NCT02083484),
an expanded access program using the approved 2 mg/kg
Q3W regimen, is open outside of the United States for pa-
tients with ipilimumab-refractory melanoma.
Other studies of pembrolizumab in melanoma are
ongoing. KEYNOTE-006 (ClinicalTrials.gov identifier:
NCT01866319), a registration trial in which pembroli-
zumab 10 mg/kg Q2W (n = 279) and 10 mg/kg Q3W
(n = 277) given for 2 years are being compared with ipi-
limumab (n = 278) in patients with ipilimumab-naive
melanoma, has reported data from 2 preplanned in-
terim analyses for the 2 co-primary endpoints of PFS
and OS (based on intention to treat) [21]. The first ana-
lysis was performed for PFS after ≥260 events and at
least 6 months of follow-up. The second analysis oc-
curred for OS after ≥290 deaths in all study groups and
at least 9 months or a minimum of 12 months follow-up
had occurred (analysis cutoff date, March 3, 2015; median
duration of follow-up 7.9 months [range, 6.1–11.5]) [21].
At baseline, LDH level was elevated in 32.4 % of patients,
65.3 % of patients had stage M1c disease, 80.5 % had PD-
L1–positive tumors, 36.2 % had BRAFV600 mutant tumors,
and 9.4 % had stable brain metastases; 65.8 % of patients
had received no prior therapy for advanced disease. At the
first interim analysis 502 events had occurred and PFS
was significantly higher for both doses of pembrolizumab
compared with ipilimumab; estimated 6-month PFS was
47.3 % (Q2W schedule), 46.4 % (Q3W) and 26.5 % (ipili-
mumab) [21]. Median PFS was 5.5 months (95 % CI: 3.4–
6.9) for pembrolizumab Q2W, 4.1 months (95 % CI: 2.9–
6.9) for pembrolizumab Q3W, and 2.8 months (95 % CI:
2.8–2.9) for ipilimumab. HRs for the pembrolizumab
groups compared with ipilimumab were 0.58 (95 % CI:
0.46–0.72; P < 0.001) and 0.58 (95 % CI: 0.47–0.72;
P < 0.001) for Q2W and Q3W schedules, respectively [21].
There was no difference in PFS in any subgroup with any
of the 3 treatments. At the second interim analysis, 289
deaths had occurred, and OS estimates at 1 year were
74.1 %, 68.4 %, and 58.2 % for pembrolizumab Q2W, pem-
brolizumab Q3W, and ipilimumab, respectively. Com-
pared with the ipilimumab group, HR was 0.63 (95 % CI:
0.47–0.83; P < 0.0005) in the Q2W arm and 0.69 (95 % CI:
0.52–0.9; P = 0.0036) in the Q3W arm [21]. Median OS
has not been reached in any group. OS was similar across
subgroups, with the exception of PD-L1 expression. For
PD-L1-negative tumors, HR was 0.91 in the Q2W arm
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ORR was significantly higher in the pembrolizumab arms
(33.7 % for Q2W, 32.9 % for Q3W; P < 0.001 for either
schedule) compared with ipilimumab (11.9 %) [21].
Complete responses were seen in 5.0 %, 6.1 %, and 1.4 %,
respectively. Median duration of response was not
achieved in any group. Median time to response was
86 days (range, 32–212), 85 days (range, 36–251), and
87 days (range, 80–250), respectively, and over 88 % of re-
sponses in all groups were ongoing at the time of analysis
[21]. The data and safety monitoring committee has rec-
ommended that pembrolizumab be made available to pa-
tients who have progressed in the ipilimumab group.
Follow-up for safety and survival will continue until final
analysis [21].
Additional trials of pembrolizumab in melanoma are ex-
ploring the potential to treat asymptomatic brain disease
(NCT02085070) and the activity and safety of combination
therapy with pegylated interferon alpha (NCT02112032
and NCT02089685 [KEYNOTE-029]), dabrafenib and tra-
metinib (KEYNOTE-022, NCT02130466), and ipilimumab
(KEYNOTE-029, NCT02089685).
Lung carcinoma
Results from the NSCLC cohort of KEYNOTE-001 (Fig. 1)
have been recently reported [22]. A total of 495 patients
were enrolled and received ≥1 cycle of pembrolizumab.
Patients received either 2 mg/kg Q3W (n = 6), or 10 mg/
kg Q2W (n = 202) or Q3W (n = 287) (Fig. 1) and response
was assessed per RECIST v1.1. Across doses, schedules,
and degrees of PD-L1 expression, ORR was 19.4 %
(95 % CI: 16.0–23.2) [22]. ORR was 24.8 % (95 % CI:
16.7–34.3) in treatment-naive patients (n = 101) and
18.0 % (95 % CI: 14.4–22.2) in treatment-naive patients
(n = 101), and 18.0 % (95 % CI: 14.4–22.2) in previously
treated patients (n = 394). There was no difference in re-
sponse according to histology, dose, or schedule [22].
Pembrolizumab demonstrated an ORR of 33.3 % (95 %
CI: 4.3–77.7) at 2 mg/kg Q3W (n = 6), 19.2 % (95 % CI:
14.8–24.2) at 10 mg/kg Q3W (n = 287), and 19.3 %
(95 % CI: 14.1–25.4) at 10 mg/kg Q2W (n = 202) [22].
Previous or current smokers had an ORR of 22.5 %
compared with 10.3 % in nonsmokers. The median dur-
ation of response at the time of analysis (August 2014)
was 12.5 months (range, 1.0–10.4) in all patients,
10.4 months (range, 1–10.4) in previously treated pa-
tients, and 23.3 months (range, 1–23.3) in treatment-
naive patients. Survival analysis showed a median PFS
of 3.7 months (95 % CI: 2.9–4.1) for all patients
(3 months for previously treated patients [95 % CI: 2.2–
4.0] and 6 months [95 % CI: 4.1–8.6] for treatment-
naive patients). Median OS was 12 months (95 % CI:
9.3–14.7) for all patients (9.3 months for previously
treated patients [95 % CI: 8.4–12.4] and 16.2 months[95 % CI: 16.2–not reached] for treatment-naive pa-
tients) [22]. As presented in more detail below in the
“Biomarkers of Response” section, there was a relation-
ship between degree of PD-L1 expression and outcomes
such that patients with PD-L1 expression in ≥50 % of
tumor cells had higher ORR and longer PFS and OS
compared with patients who had PD-L1 expression in
<50 % of tumor cells. Treatment was well tolerated, with
9.5 % of patients overall experiencing grade ≥3
treatment-related AEs, most commonly pneumonitis
(1.8 %) [22].
Several trials in patients with NSCLC are ongoing to
evaluate pembrolizumab as a single agent or in combin-
ation as first-line or second-line treatment. KEYNOTE-042
(NCT02220894) and KEYNOTE-024 (NCT02142738) are
randomized phase III studies of patients with treatment-
naive, PD-L1-positive advanced or metastatic NSCLC
without sensitizing EGFR mutation or ALK transloca-
tion. Patients are being randomized to either pembroli-
zumab 200 mg Q3W or platinum-containing
chemotherapy. A total of 1240 patients will be recruited
to KEYNOTE-042 and 300 will be enrolled in
KEYNOTE-024, with OS and PFS as the primary end
points, respectively. KEYNOTE-010 (NCT01905657)
will evaluate pembrolizumab as second-line therapy in
comparison with docetaxel following progression on
platinum-based chemotherapy in 920 patients. In
KEYNOTE-021 (NCT02039674), 320 patients will be
recruited in a 2-part, multiarm study. Part 1 will deter-
mine the optimal combination of pembrolizumab with
chemotherapy, targeted agents, or ipilimumab; part 2
will compare pembrolizumab in combination with
chemotherapy to chemotherapy alone, and will assess
the optimal combination of ipilimumab and pembroli-
zumab. KEYNOTE-037 (NCT02178722) is designed to
test the combination of pembrolizumab and the indo-
leamine 2,3-dioxygenase (IDO1) inhibitor INCB024360.
Part 1 will be a phase I study in advanced solid tumors
to determine the optimal phase II dose of INCB024360
in combination with pembrolizumab 2 mg/kg Q3W.
Part 2 will test the combination in NSCLC in a ran-
domized, double-blind, phase II study.
Additional tumor types
Pembrolizumab has demonstrated efficacy in other ad-
vanced solid tumors and hematologic malignancies.
KEYNOTE-012, which recruited patients with ≥1 % PD-L1
tumor cell positivity to receive pembrolizumab 10 mg/kg
Q2W for up to 24 months, included head and neck cancer
[23], gastric carcinoma [24], urothelial carcinoma [25], and
triple-negative breast cancer [26] (Table 1). In gastric car-
cinoma, 40 % (65/162) of screened patients were PD-L1
positive [24]. Thirty-nine patients with gastric cancer were
enrolled (19 from Asia and 20 from the rest of the world)
Table 1 Summary of pembrolizumab efficacy and safety in advanced malignancies other than melanoma and NSCLC
Study (clinical
trials.gov identifier)
N Study design Pembrolizumab
dose/schedule
Efficacy (RECIST v1.1, central review) Safety
HNSCC




10 mg/kg Q2W • ORR: 20 % • Grade 3-4 DRAEs: 17 %
(NCT01848834) [23] • Median duration of response:
NR (range 8+ to 41+ weeks)
• DR discontinuations:
not reported
• Median PFS: 9.3 weeks
(95 % CI: 8.0–20.1)
• DR deaths: none
• Median OS: 12.6 months
• 6-month OS rate: 65 %
Gastric cancer




10 mg/kg Q2W • ORR: 22 % • Grade 3-4 DRAEs: 10 %
(NCT01848834) [24] • Median duration of response:
24 weeks (range 8+ to 33+ weeks)
• DR discontinuations: none
• Median PFS: 1.9 months
(95 % CI: 1.8–3.5)
• DR deaths: n = 1
• Median OS: NR
• 6-month OS rate: 69 %
Urothelial cancer




10 mg/kg Q2W • ORR: 25 % • Grade 3-4 DRAEs: 15 %
(NCT01848834) [25] • Median duration of response:
NR (range 16 to 50+ weeks)
• DR discontinuations: 3 %
• Median PFS: 2 months
(95 % CI: 1.7–4.0)
• DR deaths: none
• Median OS: 9.3 months
• 12-month OS rate: 55 %
Triple-negative breast cancer
KEYNOTE-012 32 Phase I, international,
open-label, nonrandomized
cohort of PD-L1-positive
advanced triple-negative breast cancer
10 mg/kg Q2W • ORR: 19 % • Grade 3-4 DRAEs: 16 %
(NCT01848834) [26] • Median duration of response:
NR (range 15 to 40+ weeks)
• DR discontinuations: 3 %
• Median PFS: 1.9 months
(95 % CI: 1.7–5.4)
• DR deaths: n = 1
• OS: not reported
Hodgkin lymphoma




10 mg/kg Q2W • ORR: 66 % • Grade 3-4 DRAEs: 10 %
(NCT01953692) [27] • Median duration of response:
NR (range 1+ to 185+ days)
• DR discontinuations:
not reported
• PFS: not reported • DR deaths: n = 0
• OS: not reported
Clinical data reported to date
Abbreviations: AE adverse event; CI confidence interval; DR drug-related; DRAE drug-related AE; HNSCC head and neck squamous cell carcinoma; NR not reached;
NSCLC non-small cell lung cancer; ORR overall response rate; OS overall survival; PD-L1 programmed death receptor ligand 1; PFS progression-free survival; Q2W
once every 2 weeks; Q3W once every 3 weeks
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prior therapies and median follow-up was 8.8 months at
the time of reporting. ORR was 22 % (95 % CI: 10–39),
6-month PFS was 24 %, and 6-month OS was 69 % [24].
In urothelial carcinomas, 33 patients were treated, 52 %
of whom had received ≥2 previous treatments [25].
ORR was 25 % (95 % CI: 10–44), median PFS was
2 months, and median OS was 12.7 months [25].Patients with triple-negative breast cancer enrolled in
KEYNOTE-012 had an ORR of 18.5 % (5/27 evaluable
patients), 7 patients had SD, and median PFS was
1.9 months [26]. Of the 104 patients with head and neck
cancer who were screened, 81 (78 %) were PD-L1 posi-
tive (23 human papillomavirus [HPV] positive and 35
HPV negative) [23]. ORR was 20 % regardless of HPV
status [23]. In KEYNOTE-013, ORR was 66 % in
Khoja et al. Journal for ImmunoTherapy of Cancer  (2015) 3:36 Page 7 of 13patients with Hodgkin lymphoma [27] (Table 1). More
recently, preliminary data from the mesothelioma co-
hort of the KEYNOTE-028 study of pembrolizumab
for advanced solid tumors showed ORR in 28 % (7/25)
of patients, including SD in 48 % (12/25) [28].Toxicity
Toxicity reported to date, primarily in melanoma pa-
tients, has been manageable and not treatment limiting
in the majority of patients. The most common AEs have
been fatigue, rash, pruritus, arthralgia, amylase elevation,
and diarrhea. Other toxicities such as nephritis or colitis
are rare and there have also been case reports of individ-
ual idiosyncratic reactions, including diabetes and heart
failure [29, 30]. AEs are generally immune-related but
manageable with corticosteroids and interruptions of
dosing. The specific management of immune-related
AEs has followed guidelines drawn from previous ex-
perience with ipilimumab; to date, a number of treat-
ment guidelines exist [31, 32].
Common AEs of any grade detected in patients en-
rolled in KEYNOTE-001 are described in Table 2. Few
grade 3 or above AEs have been seen; however, the most
prevalent are pneumonitis, diarrhea, hepatitis, and
endocrine-related AEs such as hyper- or hypothyroidism.
Grade 3 or above AEs reported in patients treated in
KEYNOTE-001 are described in Table 3. The incidence
of grade ≥3 AEs was 14 % in the nonrandomized melan-
oma cohorts (n = 135) [17] and 12 % in the randomly
assigned ipilimumab-refractory patients (n = 173) [13].
In KEYNOTE-006 patients with melanoma, the pembro-
lizumab arms had less toxicity compared with ipilimu-
mab; incidence of grade ≥3 toxicity was 13.3 %, 10.1 %,
and 19.9 % for the 10 mg/kg Q2W vs 10 mg/kg Q3W
doses of pembrolizumab and ipilimumab, respectively
[21]. The rate of drug discontinuation secondary to AEs
for these groups was 4.0 %, 6.9 %, and 9.4 %, respect-
ively. Common AEs observed with pembrolizumab were
fatigue, diarrhea, hyperthyroidism, hypothyroidism, rash,
and pruritus; grade ≥3 diarrhea occurred in >1 % of pa-
tients (2.5 % and 1.1 %, respectively, for Q2W vs Q3W
schedules) [21]. Grade ≥3 colitis occurred in 1.4 % and
2.5 % and grade ≥3 hepatitis in 1.1 % and 1.8 % at the
Q2W and Q3W schedules, respectively, detailed in Ta-
bles 2 and 3 [21].
Lung patients treated on KEYNOTE-001 had a similar
safety profile to that observed in patients with melan-
oma. The incidence of AEs of grade ≥3 was 9.5 %, with
pneumonitis (1.8 %), dyspnea (3.8 %), decreased appetite
(1 %), and asthenia (1 %) having the highest frequencies
[22]. Pneumonitis of any grade occurred in 3.6 % of pa-
tients [22]. To date, no specific associations in patients
with NSCLC have been reported between the risk ofpneumonitis and previous or subsequent radiotherapy
after progression on an anti-PD-1/PD-L1 agent. There
was 1 treatment-related death (pneumonitis) [22].
Median follow-up duration in all reported and pub-
lished trial cohorts has been short, and mature data on
long-term toxicity are awaited. The kinetics of toxicity
will be important in managing patients on pembrolizu-
mab, especially in patients undergoing continued treat-
ment within the context of durable CR or PR. Important
issues for future investigation include how the profile of
AEs will alter with combinatorial immune or multimod-
ality therapies, such as vaccines and radiation therapy.
Biomarkers of response
The first phase I trials to demonstrate safety and activity
of agents targeting the PD-1/PD-L1 axis evaluated nivolu-
mab [33] and BMS-936559 [34], respectively. Immunohis-
tochemical (IHC) staining for PD-L1 was performed in a
variety of biopsy samples obtained from these patients
both before and during study treatment, and responses
appeared to correlate, albeit incompletely, with PD-L1 ex-
pression. Lack of a universally validated antibody or assay
for PD-1 and PD-L1 remains a hindrance in determining
if tumor and/or accessory cell expression of PD-L1 or in-
filtrating PD-1-expressing lymphocytes may be used as a
predictive biomarker for anti-PD-1 and PD-L1 agents.
Furthermore, different IHC expression cutoff levels have
been used to evaluate the predictive role of PD-L1 expres-
sion. PD-L1 expression might be dynamic, and its expres-
sion may change in an ongoing adaptive immune response.
It may therefore be best used as a reflection or marker of
the immune response at a particular time point to guide
the choice of monotherapy or combination therapy.
To date, data for the relationship between pembroli-
zumab and PD-L1 expression are largely limited to data
from KEYNOTE-001. In a 195-patient training set de-
rived from the melanoma population of KEYNOTE-001
and using a 1 % cutoff to determine positivity, 71 % of
the 125 evaluable patients had PD-L1-positive tumors
as assessed using a prototype IHC assay and the 22C3
antibody [35]. PD-L1 positivity was associated with a
higher ORR by RECIST v1.1 (49 % vs 13 %; P = 0.0007)
and improved PFS (median PFS 11 months vs 3 months;
HR = 0.52; 95 % CI: 0.32–0.86; P = 0.0051), but not OS
(6-month OS was 91 % in positive vs 79 % in negative
PD-L1 tumors; P = 0.3165) [35]. In an independent
validation set of 216 patients with melanoma in
KEYNOTE-001, 82 % of the 150 evaluable patients had
PD-L1-positive tumors [36]. Similar to the training set,
PD-L1 positivity vs PD-L1 negativity was associated
with a higher ORR (36 % vs 4 %; P = 0.0022), longer
PFS (HR = 0.43; 95 % CI: 0.27–0.69; P = 0.0002), and
improved OS (HR = 0.33; 95 % CI: 0.18–0.63; P =
0.0042) [36]. Although PD-L1 positivity is correlated
Table 2 DRAEs with incidence ≥5 % observed in patients from KEYNOTE-001 and KEYNOTE-006
AE, % Nonrandomized and randomized
cohorts KEYNOTE-001
NSCLC cohorts KEYNOTE-001 KEYNOTE-006 KEYNOTE-006
(n = 411) [16] (n = 495) [22] (melanoma, 10 mg/kg Q2W,
n = 278) [21]
(melanoma, 10 mg/kg Q3W,
n = 277) [21]
Fatigue 36 19 21 19
Pruritus 24 11 14 14
Rash 20 10 15 13
Arthralgia 16 9 9 12
Diarrhea 16 8 17 14
Nausea 12 8 10 11
Vitiligo 11 NR 9 11
Asthenia 9 5 12 11
Cough 9 2 4 4
Myalgia 9 3 7 2
Headache 8 2 3 2
Hypothyroidism 8 7 10 9
Decreased appetite 7 11 6 7
Dyspnea 7 4 1 3
Chills 6 2 1 0
Pyrexia 6 4 4 1
ALT increase 5 2 4 1
Pneumonitis 3 4 <1 2
Hyperthyroidism 1 2 7 3
Colitis <1 NR 2 4
Hepatitis <1 NR 1 2
Hypophysitis NR NR <1 <1
Nephritis NR NR 0 <1
KEYNOTE-001 included melanoma and lung cohorts; KEYNOTE-006 included patients with melanoma
Numbers given as percentages where available
Abbreviations: AE adverse event; ALT alanine aminotransferase; DRAEs drug-related AEs; NR not reported; NSCLC non-small cell lung cancer
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melanoma, given the responses seen in patients with
PD-L1-negative tumors and the high prevalence of
PD-L1 positivity, it is unlikely that PD-L1 will be used
as a selection or predictive marker for anti-PD-1 or anti-
PD-L1 agents in melanoma. Data from the registration
KEYNOTE-006 trial confirm activity in PD-L1-negative
tumors. However, only 20 % of the tumors were PD-L1
negative.
Results have differed in patients with lung cancer
treated in KEYNOTE-001 [22]. Patients in this trial
were divided (with respect to PD-L1 staining) into
training (n = 182) and validation (n = 313) groups. A
tumor biopsy was required 60 days prior to treatment
with pembrolizumab. Initial staining was performed
using the prototype assay and after a relationship was
seen between degree of PD-L1 positivity and response
(n = 51 patients recruited by that point), the trial wasamended to include a co-primary endpoint of response
in previously treated patients with high PD-L1 expres-
sion only [22]. The clinical trial assay was used for all
staining thereafter using the same 22C3 antibody. The
training set data were analyzed using receiver operating
curves (ROC) to determine the optimal expression cut-
off point. PD-L1 expression was determined as a per-
centage of carcinoma cell membranous staining [22].
During training analysis a critical 6-month period for
retention of PD-L1 antigen in tumor sections was dis-
covered. Validation therefore was only performed in
tumor samples sectioned within 6 months of biopsy
and staining. Patients, investigators and the sponsor
were masked to PD-L1-staining results until at least
5 months of follow-up [22]. In total, 129 patients were
used in the training set analysis and 204 (156 previously
treated and 48 treatment-naive) patients were included in
the validation set analysis. A cutoff of ≥50 % PD-L1
Table 3 Incidence of grade ≥ 3 DRAEs in patients from KEYNOTE-001 and KEYNOTE-006
AE, % Nonrandomized and
randomized cohorts
NSCLC cohorts KEYNOTE-006 KEYNOTE- 006
(n = 411) [16] (n = 495) [22] (melanoma, 10 mg/kg Q2W, n = 278) [21] (melanoma,10 mg/kg Q3W, n = 277) [21]
Fatigue 2 <1 0 <1
ALT increase <1 <1 0 <1
Colitis <1 NR 1 3
Decreased appetite <1 1 0 0
Diarrhea <1 <1 3 1
Dyspnea <1 4 0 <1
Headache <1 NR 0 0
Hepatitis <1 NR 1 2
Hyperthyroidism <1 NR 0 0
Hypophysitis <1 NR <1 <1
Hypothyroidism <1 <1 <1 0
Nausea <1 <1 0 <1
Pneumonitis <1 2 0 <1
Pruritus <1 0 0 0
Rash <1 <1 0 0
Arthralgia 0 <1 0 <1
Asthenia 0 1 <1 0
KEYNOTE-001 included melanoma and lung cohorts; KEYNOTE-006 included patients with melanoma
Numbers given as percentages where available
Abbreviations: AE adverse event; ALT alanine aminotransferase; DRAE drug-related AEs; NR not reported; NSCLC non-small cell lung cancer
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ROC analysis [22]. Using this cutoff in the training set,
ORR by RECIST v1.1 was 36.6 % (95 % CI: 22.1–53.1). In
the validation group, patients with measurable disease and
a score of ≥50 % staining (n = 73) had a response of 45.2 %
(95 % CI: 33.5–57.3); ORR was 43.9 % (95 % CI: 30.7–57.6)
in previously treated patients and 50 % (95 % CI: 24.7–75.3)
in treatment-naive patients. Response was lower in pa-
tients with a score of 1 %–49 % staining (ORR 15.6 %
[95 % CI: 8.3–25.6]) and ≤1 % staining (ORR 9.1 %
[95 % CI: 1.1–29.2]). ORR in all patients (measurable
and unmeasurable) was 42.3 % [22]. The difference in
response between patients with ≥50 % staining and
those with 1 %–49 % or ≤1 % staining was observed in
both previously treated and treatment-naive patients.
No additional differences in response rates were found
according to dose, schedule, or smoking status [22].
Overall prevalence of PD-L1 staining in the screened
population (n=824) using the clinical trial assay showed
23.2 % of patients to stain ≥50 % positive (24.9 % treat-
ment naive and 22.7 % previously treated), 37.6 % to
stain 1 %–49 % positive, and 39.2 % to have ≤1 % PD-L1
positivity. Only KRAS positivity was associated with a
higher PD-L1 positivity [22]. Median duration of re-
sponse was similar regardless of PD-L1 positivity, while
PFS and OS were shorter in the patients with ≤1 % and
1 %–49 % PD-L1 staining compared with those with≥50 % staining. Median PFS in the latter group was
6.3 months (95 % CI: 2.9–12.5), 6.1 months (95 % CI,
2.1-12.5) in previously treated patients and 12.5 months
(95 % CI, 2.4-12.5) in treatment naive patients. Median
OS was not reached in the ≥50 % PD-L1-positive group
[22]. Taken together, the results suggest enrichment by
PD-L1 staining for better survival outcomes in patients
treated with pembrolizumb if they have ≥50 % PD-L1-
tumor positivity. Whether PD-L1 is a prognostic marker
is yet to be determined, although a meta-analysis has
suggested that it does not have a positive effect in
NSCLC cancer [37]. Given the differences in assays and
cutoff levels used to define PD-L1 positivity, further
data and longer follow-up are required to evaluate its
use as a prognostic marker.
Although its use in lung cancer is not fully defined,
the ongoing KEYNOTE-010, KEYNOTE-024, and
KEYNOTE-042 studies of pembrolizumab are limiting
enrollment to patients with PD-L1-positive tumors.
Interestingly PD-L1 expression has also been shown to
be a predictor of response to MPDL3280A (a PD-L1
antibody), but with expression on tumor-infiltrating im-
mune cells more indicative of a response than expres-
sion on tumor cells [38].
A number of other predictive biomarkers of response
to pembrolizumab have been proposed. Analysis of the
sum of target lesions at baseline (“baseline tumor size”)
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showed that baseline tumor size below vs above the
median was found to independently predict both re-
sponse (ORR 42 % vs 25 %; P = 0.001) and OS (HR =
2.35; P < 0.001), although all patients could benefit from
treatment [39]. Baseline tumor size remained an inde-
pendent predictor of response and OS in an extended
analysis that included PD-L1 [40]. Infiltration of tumor
by CD8+ T cells at the invasive tumor margin and ex-
pression of neoepitopes have both been described asTable 4 Overview of PD-1/PD-L1 inhibitors with active clinical trials
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Abbreviations: DLBCL diffuse large B-cell lymphoma; GBM glioblastoma multiforme;
PD-L1 programmed death receptor ligand 1additional predictors of response to pembrolizumab in
melanoma and NSCLC, respectively [41, 42].
An overview of and perspective on therapeutic targeting
of the PD-1/PD-L1 axis
Several agents targeting the PD-1/PD-L1 axis are in de-
velopment, including the PD-1 inhibitors nivolumab,
AMP-224, and pidilizumab and the PD-L1 inhibitors
BMS-936559, MPDL3280A, and MEDI 4736 (Table 4).
Nivolumab and pembrolizumab are the 2 most advancedof development by cancer type
untries): advanced melanoma
ck cancer; melanoma; NSCLC; urothelial cancer; gastric/gastroesophageal
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lid tumors; myelodysplastic syndrome; pontine gliomas; ovarian cancer
untries): advanced melanoma; previously treated squamous cell NSCLC
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leukemia; anal carcinoma; B-cell non-Hodgkin lymphoma; cervical cancer;
dgkin lymphoma; nasopharyngeal carcinoma; chronic lymphocytic leukemia;
oma; urothelial cancer; myelofibrosis
lid tumors; breast cancer; chronic myeloid leukemia; colorectal cancer;
; hepatocellular carcinoma; multiple myeloma; osteosarcoma; ovarian
coma
genous leukemia; follicular lymphoma; multiple myeloma; pancreatic
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lid tumors; B-cell lymphoma; cervical cancer; gastric/gastroesophageal




NSCLC non-small cell lung cancer; PD-1 programmed death receptor 1;
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alone is being studied in ≥20 tumor types. Given the
single-agent activity seen to date with all of these agents,
it remains unclear whether novel combinations will pro-
vide acceptable tolerability and greater efficacy. Nivolu-
mab in combination with ipilimumab is being evaluated
in a number of tumor types, including melanoma. Phase
II data from the CheckMate 069 double-blinded trial of
nivolumab and ipilimumab vs ipilimumab alone have
shown an objective response rate of 61 % for the combin-
ation vs 11 % for ipilimumab and placebo (P < 0.001) [43].
The primary endpoint of this trial was ORR among pa-
tients with BRAFV600 wild-type tumors. Mature data on
PFS (secondary endpoint) are awaited. Data from the
registration phase III CheckMate 067 trial (double-blind
trial of nivolumab vs ipilimumab vs combination of these
agents (ClinicalTrials.gov identifier: NCT01844505) are
eagerly awaited. Pembrolizumab is also being studied in
combination with ipilimumab in patients with melanoma
and RCC in the phase I/II KEYNOTE-029 study (Clinical-
Trials.gov identifier: NCT02089685). Other novel combi-
nations include nivolumab in combination with the
checkpoint inhibitor LAG-3 (ClinicalTrials.gov identifier:
NCT01968109) and pembrolizumab plus the IDO1 inhibi-
tor INCB024360 in KEYNOTE-037 (ClinicalTrials.gov
identifier: NCT02178722). Addition of stimulatory CD137
agonists is being evaluated in studies of nivolumab plus
urelumab (NCT02253992), and pembrolizumab plus
PF-05082566, a 4-1BB ligand inhibitor (NCT02179918).
Pembrolizumab is also being studied in combination with
pegylated interferon alpha-2b, talimogene laherparepvec,
dabrafenib, trametinib, axitinib, pazopanib, chemotherapy,
cetuximab, trastuzumab, and ADXS31-142.
Conclusions
The development of pembrolizumab from the first-in-
humans study to FDA approval for the treatment of pa-
tients with unresectable or metastatic melanoma with
disease progression following ipilimumab, and if
BRAFV600 mutation positive, a BRAF inhibitor, has oc-
curred in a record 3.6 years. Approval is likely to be ex-
tended to include other melanoma populations and
other tumor types. The dose of pembrolizumab cur-
rently approved in metastatic melanoma is 2 mg/kg
Q3W. Higher doses are being explored in other tumor
types but there have been no statistically significant dif-
ferences in responses or outcomes with 10 mg/kg on ei-
ther Q2W or Q3W schedules in KEYNOTE-001
cohorts. It is likely that the Q3W schedule will therefore
be chosen. Future trials are evaluating a fixed dose of
200 mg in a variety of carcinomas. Furthermore, mature
data are needed on patterns and kinetics of response
and toxicity. The optimum duration of treatment is un-
known, as is the risk of late serious or treatment-limitingtoxicity especially in the context of CR or near CR. Patients
in KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006
who had a confirmed complete response were allowed to
discontinue treatment and enter follow-up. Mature data on
outcomes in these patients specifically and dedicated trials
of different durations of treatment will inform on this
question.
Despite the clinical urgency to develop these agents,
well-thought-out translational research will be crucial in
determining predictive biomarkers and elucidating mecha-
nisms of resistance to plan rational therapeutic combina-
tions. For example, infiltration of CD8+ T-cells, PD-L1
staining, and the presence of other checkpoint inhibitors
may aid treatment choices by informing the use of com-
bination therapy vs monotherapy. Intrapatient heterogen-
eity in response may be further combated by adjunctive
therapies such as surgery or radiotherapy to induce an
abscopal effect. Taken together, the approval of pembroli-
zumab as a first-in-class PD-1 inhibitor has been a defin-
ing moment in immuno-oncology and promises to
accelerate the field for decades to come.
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